| Company/Division name | Hikma Pharmaceuticals USA |
| Parent company | Hikma Pharmaceuticals USA |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 1000 |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | Colombus |
| State(s) reshored to: | OH |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Image/brand, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |
